haematology

News in brief: Selinexor benefits in MM patients regardless of cytogenetic risk; Breast implant lymphoma cases predicted to surge; Gender disparity in citations a career barrier for female academics in medicine

Selinexor-based therapy benefits in MM patients regardless of cytogenetic risk A simple triplet, non-IMiD-based regimen, which uses the oral XPO1 inhibitor selinexor, has demonstrated superior benefit across several clinical outcomes compared to standard therapy with bortezomib and dexamethasone(Vd) in patients with previously treated MM. The once weekly XVd regimen showed superior PFS, ORR and TTNT ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic